Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    New depression treatments: psilocybin, esketamine and the SSRI debate

    Esketamine nasal spray is approved for treatment-resistant depression, and a synthetic psilocybin (COMP360) is under rolling FDA review after its developer reported two positive phase 3 trials.[1][2][3] No psychedelic is FDA-approved for depression yet, and independent experts say larger, longer trials are needed.[4][5] Meanwhile a 2026 HHS push to taper antidepressants drew pushback from psychiatrists.[6][7]

    Editor reviewedStrict sourcingUpdated AnalysisMental health, Health and medicine, Tech policy
    Show:

    If you are struggling or thinking about suicide, help is available now. In the US, call or text 988 or chat at 988lifeline.org.[8] In the UK and Ireland, call Samaritans free on 116 123.[9] Elsewhere, find a local helpline at findahelpline.com.[10]

    Depression treatment is changing on two fronts in 2026. New drugs aimed at treatment-resistant depression are moving through the FDA, and a federal campaign has reopened arguments about the most widely used antidepressants.[2][6] This analysis separates what is established from interpretation and forecasts. It is not medical advice; do not start, stop or change any treatment without a clinician, and do not use unregulated psychedelics on the basis of this page.[11]

    The problem new treatments target

    NIMH defines treatment-resistant depression (TRD) as no improvement after trying at least two antidepressants.[12] Compass Pathways, a psilocybin developer, estimates that about 4 million people in the US with MDD have TRD.[13] Established options for TRD include add-on medicines, ECT, which NIMH calls the “gold standard”, and rTMS.[12][14]

    Esketamine: the rapid-acting precedent

    Esketamine nasal spray (Spravato) is FDA-approved for TRD in adults and, since January 2025, can be used without an oral antidepressant.[1][15] NIMH says it typically acts within a couple of hours.[16] Because of risks of sedation, dissociation, respiratory depression and misuse, it is given only in certified settings under a restricted program, and it carries a boxed warning.[17][18]

    Esketamine matters for the psychedelic debate because it established a supervised, in-clinic delivery model for a fast-acting drug with abuse potential. Any approved psilocybin product would probably need similar restrictions, which shapes cost and access as much as efficacy does.

    Psilocybin: what the evidence shows

    A key peer-reviewed psilocybin trial, a phase 2 study in the NEJM in 2022, randomised 233 adults with TRD to a single dose of synthetic psilocybin (25 mg, 10 mg or 1 mg as control) with psychological support.[19] At three weeks the 25 mg group improved more than the control (a 6.6-point MADRS difference); the 10 mg group did not, and sustained response at 12 weeks was not clearly supported.[20] Adverse events occurred in 77% of participants, and suicidal ideation, behaviour or self-injury occurred in all dose groups.[21] The trial was funded by the developer.[19]

    Compass reports that COMP360 met its goals in two phase 3 trials, COMP005 and COMP006, with more than 1,000 participants across its TRD programme.[3] By the company’s account, 39% of COMP006 and 25% of COMP005 participants had at least a 25% reduction in MADRS scores at week 6, maintained on average through week 26.[22] These figures are the company’s own summaries; we have not seen independent analyses of the phase 3 data.[3]

    The company’s chosen responder threshold (a 25% score reduction) is lower than the 50% reduction the NEJM trial used to define response, so the two sets of numbers are not directly comparable.[22][23] Independent analysts at Penn’s Leonard Davis Institute describe the evidence as promising but limited.[5]

    Regulatory status, October 2026

    In April 2026 the FDA granted Compass a rolling NDA submission and selected COMP360 for a Commissioner’s National Priority Voucher, which can shorten review to one to two months after filing.[2][24] Separately, Executive Order 14401, signed on 18 April 2026, directs such vouchers to psychedelic drugs with Breakthrough Therapy designation, sets up a Right to Try pathway and allocates at least $50 million for state partnerships.[25][26] The order asks for a prompt rescheduling review of Schedule I products that complete phase 3, but it did not change psilocybin’s legal status.[27][28]

    Compass expects to complete its application in the fourth quarter of 2026 and to launch in the first half of 2027, subject to FDA approval and DEA rescheduling.[2][29] With a priority voucher, an FDA decision in early 2027 is plausible, but the timeline depends on the filing being complete and accepted, and on any advisory committee. We would treat approval as likely but not certain, and broad access as further away because of rescheduling, state rules and clinic capacity.

    The 2026 antidepressant controversy

    In May 2026 HHS Secretary Robert F. Kennedy Jr. announced policies to encourage clinicians to help patients taper off antidepressants such as SSRIs when appropriate, including training, clinical guidance and billing changes.[6] HHS’s letter to clinicians said psychiatric medications can play an important and at times essential role.[30] Under the plan, SAMHSA is to publish prescribing data and guidance, and CMS is to issue billing guidance and expand access to talk therapy.[31] An HHS spokesperson said there had been no discussions about banning SSRIs.[32]

    American Psychiatric Association leaders called the overprescribing framing an oversimplification and said the main problem is access to care.[7] The APA’s chief executive said Kennedy’s past claims that SSRIs cause violence, addiction and withdrawal worse than heroin are false.[33] The APA also said it supports better training on safe tapering, and its president joined an HHS panel on tapering guidance.[34] About one in six US adults report taking an antidepressant.[35]

    There is more agreement here than the headlines suggest. Both HHS and the APA endorse informed consent and supervised tapering where appropriate.[30][34] The dispute is about emphasis and messaging: whether the main risk is overuse of medicines, or people stopping effective treatment abruptly, or never getting care at all.[7][36] For patients, the practical advice from NIMH is unchanged: talk to a clinician before stopping any medicine.[11]

    Watch for SAMHSA’s promised prescribing data and tapering guidance, and for any FDA label reviews. If guidance emphasises gradual, supervised tapering, it is likely to align with existing clinical practice; if it questions SSRI effectiveness broadly, expect further professional opposition.

    For background see the depression treatments guide; for research on circuit-level tools in psychiatry, see our analysis of optogenetics’ route to psychiatry.

    Competing views

    A new class for hard-to-treat depression

    Treatment-resistant depression leaves many people without relief. Esketamine showed rapid-acting drugs can reach patients through supervised clinic models, and psilocybin's developer reports benefit lasting months after one or two doses. Federal policy is now actively speeding review.[16][22][24][26]

    The evidence is not mature yet

    The main peer-reviewed phase 2 psilocybin trial in TRD found a three-week benefit at one dose, no clear 12-week sustained response, and frequent side effects. The phase 3 figures available here come from the company. Speed should not replace rigour.[20][21][3][5]

    Fix access to proven care first

    Most people with depression in rich countries get no treatment, and therapy is hard to reach. Psychiatrists argue the bigger problem is access, not over- or under-use of any one drug class.[36][37][7]

    Next in the crash course

    Questions readers ask

    Is psilocybin FDA-approved for depression?

    No. As of October 2026 no psilocybin product was approved. Compass Pathways' COMP360 was under a rolling New Drug Application, with the company aiming to complete it in the fourth quarter of 2026.[4][2]

    When could psilocybin therapy be available in the US?

    Compass says it expects a launch in the first half of 2027, but only if the FDA approves it and the DEA reschedules psilocybin. That is a company forecast, not a certainty.[29]

    What did the 2022 NEJM psilocybin trial find?

    In 233 adults with treatment-resistant depression, a single 25 mg dose reduced depression scores more than a 1 mg control at three weeks, but not clearly at 12 weeks. Side effects affected 77% of participants.[19][20][21]

    Is the government banning SSRIs?

    No ban was announced. In May 2026 HHS launched a plan to encourage tapering when appropriate, and an HHS spokesperson said there had been no discussions about banning SSRIs.[6][32]

    What did the April 2026 executive order on psychedelics do?

    Executive Order 14401 told the FDA to give priority vouchers to eligible psychedelic drugs, set up a Right to Try pathway, funded state research partnerships and asked for a fast rescheduling review after phase 3 success. It did not change the drugs' legal status.[26][27][28]

    Sources

    · 37 claims from 17 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      The current Spravato (esketamine) label indicates it for treatment-resistant depression in adults, as monotherapy or with an oral antidepressant. confirmedas of 2026-10-11

    2. [2]

      In April 2026 the FDA granted Compass a rolling New Drug Application submission and review for COMP360; the company said some modules were submitted and it expected to complete all modules in the fourth quarter of 2026. confirmedas of 2026-08-05

    3. [3]

      Compass Pathways reports that its synthetic psilocybin COMP360 met its goals in two phase 3 trials in treatment-resistant depression (COMP005 and COMP006) involving more than 1,000 participants. reportedas of 2026-08-05

    4. [4]

      As of October 2026 no psilocybin product had been approved by the FDA for depression; Compass described COMP360 as investigational and its approval as pending a completed NDA. confirmedas of 2026-10-11

    5. [5]

      Experts at the University of Pennsylvania's Leonard Davis Institute said psychedelic-assisted therapies show promise but the evidence remains limited and larger, more rigorous trials are needed before widespread adoption. reportedas of 2026-10-11· interpretation

    6. [6]

      In early May 2026 HHS Secretary Robert F. Kennedy Jr. announced policies to encourage clinicians to help patients taper off antidepressants such as SSRIs when appropriate, including new training, clinical guidance and changes to insurance billing. confirmedas of 2026-05-25

    7. [7]

      American Psychiatric Association leaders called the overprescribing framing an oversimplification and said the main problem is that many people cannot access timely mental health care. confirmedas of 2026-07-02

    8. [8]

      The 988 Suicide & Crisis Lifeline provides free, confidential emotional support by call, text or chat to people in suicidal crisis or emotional distress 24 hours a day across the US and its territories, through a network of over 200 local crisis centers. confirmedas of 2026-10-11

    9. [9]

      In the UK and Ireland, Samaritans can be called free on 116 123, day or night. confirmedas of 2026-10-11

    10. [10]

      Find A Helpline lists free, confidential helplines verified with crisis centers in more than 175 countries. confirmedas of 2026-10-11

    11. [11]

      NIMH advises talking to a health care provider before starting or stopping any medication. confirmedas of 2026-10-11

    12. [12]

      NIMH defines treatment-resistant depression as not getting better after trying at least two antidepressants; one option is adding a different type of medication, such as an antipsychotic or anticonvulsant. confirmedas of 2026-10-11

    13. [13]

      Compass Pathways estimates that approximately 4 million people in the US with major depressive disorder live with treatment-resistant depression. reportedas of 2026-08-05

    14. [14]

      NIMH says ECT is still considered the "gold standard" for treatment-resistant depression, while strong clinical evidence supports rTMS in reducing depressive symptoms. confirmedas of 2026-10-11

    15. [15]

      On 21 January 2025 Johnson & Johnson announced US approval of Spravato as a monotherapy for adults with treatment-resistant depression; it was previously approved for use alongside an oral antidepressant. confirmedas of 2025-01-21

    16. [16]

      NIMH describes esketamine as an FDA-approved nasal spray for treatment-resistant depression, given in a doctor's office, clinic or hospital, that typically acts within a couple of hours. confirmedas of 2026-10-11

    17. [17]

      Because of risks of sedation, dissociation, respiratory depression, abuse and misuse, Spravato is available only through a restricted program (the Spravato REMS) and can be administered only in certified healthcare settings. confirmedas of 2026-10-11

    18. [18]

      Spravato carries a boxed warning covering sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. confirmedas of 2026-10-11

    19. [19]

      A phase 2 double-blind trial published in the NEJM in 2022 randomised 233 adults with treatment-resistant depression to a single dose of synthetic psilocybin (25 mg, 10 mg or a 1 mg control) with psychological support; it was funded by COMPASS Pathfinder. confirmedas of 2022-11-03

    20. [20]

      In that trial the 25 mg dose, but not 10 mg, reduced depression scores significantly more than 1 mg over three weeks (MADRS difference -6.6 points), but sustained response at 12 weeks was not generally supportive. confirmedas of 2022-11-03

    21. [21]

      Adverse events occurred in 77% of participants in the 2022 psilocybin trial, including headache, nausea and dizziness, and suicidal ideation or behaviour or self-injury occurred in all dose groups; the authors said larger and longer trials were needed. confirmedas of 2022-11-03

    22. [22]

      Compass says 39% of participants in COMP006 and 25% in COMP005 achieved at least a 25% reduction in MADRS depression scores at week 6, maintaining benefit on average through at least week 26. reportedas of 2026-08-05

    23. [23]

      The 2022 NEJM psilocybin trial's primary end point was change in MADRS score at week 3; secondary end points defined response as a decrease of at least 50% from baseline and remission as a MADRS score of 10 or less. confirmedas of 2022-11-03

    24. [24]

      The FDA selected COMP360 for a Commissioner's National Priority Voucher, which entitles a company to enhanced communication and a shortened 1–2 month review after an NDA is filed; COMP360 also holds Breakthrough Therapy designation for TRD. confirmedas of 2026-08-05

    25. [25]

      On 18 April 2026 President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness", which encourages research on psychedelic drugs for mental health conditions. confirmedas of 2026-04-22

    26. [26]

      Executive Order 14401 directs the FDA to give National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy designation, directs FDA and DEA to set up a Right to Try access pathway, and allocates at least $50 million to partner with states on psychedelic research. confirmedas of 2026-04-22

    27. [27]

      The order also tells the Attorney General, consulting HHS, to begin and complete a review of any Schedule I product that has successfully completed phase 3 trials for a serious mental health disorder so that rescheduling, if appropriate, can proceed. confirmedas of 2026-04-22

    28. [29]

      Compass expects a US commercial launch of COMP360 in the first half of 2027, subject to FDA approval and subsequent DEA rescheduling of psilocybin. reportedas of 2026-08-05· forecast

    29. [30]

      HHS's "Dear Colleague" letter acknowledged that psychiatric medications can play an important and at times essential role, while encouraging providers to regularly review risks with patients and offer non-drug options. confirmedas of 2026-05-07

    30. [31]

      Under the plan, SAMHSA is to publish prescribing-trend data and clinical guidance, and CMS is to issue billing guidance for tapering and expand access to alternatives such as talk therapy. reportedas of 2026-05-07

    31. [32]

      An HHS spokesperson said the department had had no discussions about banning SSRIs, and reporting described the steps as not affecting patients' access to antidepressants. reportedas of 2026-05-25

    32. [33]

      APA chief executive Marketa Wills said Kennedy's claims that SSRIs cause violence, addiction and withdrawal worse than heroin are false; NPR noted he has claimed without evidence that these medications cause mass shootings. confirmedas of 2026-07-02

    33. [34]

      The APA said it supports better training on safe prescribing and tapering, and its president was to join an HHS panel developing clinical guidance on tapering antidepressants. confirmedas of 2026-07-02

    34. [35]

      About one in six US adults (16.6%, per a 2026 study cited by the New York Times) report currently taking an antidepressant. confirmedas of 2026-07-02

    35. [36]

      WHO says only about one third of people with depression in high-income countries receive mental health treatment, citing lack of investment, too few trained providers and stigma as barriers. confirmedas of 2026-09-11

    36. [37]

      Among people with depression in the NHANES data, 43.0% of females and 33.2% of males reported receiving counseling or therapy from a mental health professional in the past 12 months. confirmedas of 2025-04-30

    Revision history (1)
    1. Page created.

    Created Oct 11, 2026. Last reviewed by an editor on Oct 11, 2026. Next scheduled review: Dec 31, 2026.

    Cite this page

    "New depression treatments: psilocybin, esketamine and the SSRI debate." ContentLora, updated Oct 11, 2026. https://contentlora.com/analysis/new-depression-treatments-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    ☰ Contents